A study compared the cost effectiveness of first-line biparametric MRI testing versus first-line PSA screening for prostate cancer. The study found that first-line PSA with second-line multiparametric MRI was more cost effective than biparametric MRI as a first-line approach. While biparametric MRI showed potential in reducing prostate cancer deaths and increasing life-years, it also led to more biopsies and overdiagnoses. The researchers highlighted the importance of reducing false-positive results and overdiagnoses to improve cost effectiveness in prostate cancer screening strategies. Cost effectiveness analyses play a crucial role in guiding clinical practice and should be considered in guideline recommendations for physicians.
Source link
Prostate-specific antigen screening more cost effective than first-line MRI
